Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2002
06/27/2002US20020081306 Methods of preventing or treating cardiovascular, cerebrovascular and thrombotic disorders with tumor necrosis factor antagonists
06/27/2002US20020081292 Anthelmintic composition
06/27/2002US20020081291 Alpha-bungarotoxin molecules and uses thereof
06/27/2002US20020081279 In vitro manipulation of a plasmid-cloned chicken embryo lethal orphan (CELO) virus DNA, suitable for the production of vectors for gene therapy and as a vaccine against infectious diseases in human and animals, particularly birds
06/27/2002US20020081267 Toothpaste, gel, or mouthwash comprising emulsifier, triclosan, and surfactant (cetylpyridinium chloride); anticaries agents
06/27/2002US20020081266 Spray dried powders for pulmonary or nasal administration
06/27/2002US20020081263 Methods for decreasing beta amyloid protein
06/27/2002US20020078948 Method for generating an aerosol
06/27/2002DE10137038A1 N-3,7 Substituted 1-Methylxanthine Derivates Displaying Inhibitory Activites on Type Five Phosphodiesterase N-Substituted 3,7-methylxanthine derivative Displaying 1 Inhibitory Activites on phosphodiesterase Type Five
06/27/2002DE10131641A1 St. John's wort extracts having reduced chlorophyll and proanthocyanidin contents, useful as topical medicaments, e.g. for treating stomatitis, acne, viral infections or psoriasis
06/27/2002DE10064387A1 Redispersible dry powder containing oxygen-containing carotenoid, useful e.g. as dye in foods, feed or pharmaceuticals, prepared in presence of partially degraded soya protein as protective colloid
06/27/2002DE10064105A1 Neue Substituierte Imidazotriazinone New Substituted imidazotriazinones
06/27/2002DE10063884A1 Pharmaceutical preparation, useful for the treatment of cardiovascular and pulmonary diseases, comprises benzothienopyrimidine derivatives and calcium antagonists
06/27/2002DE10063433A1 Verwendung von DNA-Reparatur-Enzymen als MMP-1-Inhibitoren The use of DNA repair enzymes as MMP-1 inhibitors
06/27/2002DE10063076A1 Verwendung von 5-Aminolävulinsäure zur Restenose-Prophylaxe Use of 5-aminolevulinic acid for restenosis prophylaxis
06/27/2002CA2756207A1 Compositions of estrogen-cyclodextrin complexes
06/27/2002CA2714357A1 Mutations in neuronal gene sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus
06/27/2002CA2442181A1 Method for purification of lactose
06/27/2002CA2436699A1 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
06/27/2002CA2436288A1 Thrombopoietin mimetics
06/27/2002CA2433165A1 Methods for reducing chronic stress in mammals
06/27/2002CA2433018A1 Thiazolyl inhibitors of tec family tyrosine kinases
06/27/2002CA2432992A1 Fab i and inhibition of apicomplexan parasites
06/27/2002CA2432908A1 Diamines as modulators of chemokine receptor activity
06/27/2002CA2432839A1 Method for the prevention, inhibition, or treatment of vaginitis and/or bacterial vaginosis using polystyrene sulfonate
06/27/2002CA2432807A1 1,1-dioxo-2h-1, 2-benzothiazine-3-carboxamide derivatives, method for preparing same and pharmaceutical compositions comprising same
06/27/2002CA2432797A1 Local regional chemotherapy and radiotherapy using in situ hydrogel
06/27/2002CA2432638A1 Therapeutic combination of amlodipine and benazepril
06/27/2002CA2432531A1 Use of dna repair enzymes as mmp-1 inhibitors
06/27/2002CA2432500A1 Novel therapeutic use of a thienylcyclohexylamine derivative
06/27/2002CA2432429A1 Macrolide antibiotics
06/27/2002CA2432417A1 Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors
06/27/2002CA2432282A1 Therapeutic combination of amlodipine and benazepril/benazeprilat
06/27/2002CA2432066A1 Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders
06/27/2002CA2432035A1 Triglyceride depressant composition
06/27/2002CA2431995A1 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
06/27/2002CA2431994A1 Method for the production of polyfructans
06/27/2002CA2431985A1 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
06/27/2002CA2431965A1 Novel substituted imidazotriazinones as pde ii-inhibitors
06/27/2002CA2431891A1 Mutations in neuronal gene sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus
06/27/2002CA2431884A1 Neocentromere-based mini-chromosomes or artificial chromosomes
06/27/2002CA2431767A1 Substituted pyrrolidines as ccr-3 receptor antagonists
06/27/2002CA2431721A1 Tetracyclic derivatives as spla2 inhibitors
06/27/2002CA2431592A1 Benzimidazole and pyridylimidazole derivatives as ligands for gaba receptors
06/27/2002CA2431588A1 Benzylamine derivatives and their use as thrombin inhibitors
06/27/2002CA2431495A1 A process for preparing vegetable oil fractions rich in non-tocolic, high-melting, unsaponifiable matter
06/27/2002CA2431483A1 Antiviral agents
06/27/2002CA2431278A1 Use of triaminobenzene derivatives for treatment of anxiety disorders
06/27/2002CA2431147A1 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
06/27/2002CA2431139A1 Oxidoreductases
06/27/2002CA2431077A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
06/27/2002CA2431074A1 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (1)
06/27/2002CA2431028A1 Tetracyclic carbazole derivates and their use as spla2 inhibitors
06/27/2002CA2431023A1 Substituted benzoindoles as spla2 inhibitors
06/27/2002CA2430918A1 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
06/27/2002CA2430808A1 Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
06/27/2002CA2430782A1 Analogues of thiocoraline and be-22179
06/27/2002CA2430595A1 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side-effect
06/27/2002CA2429519A1 Novel human secreted proteins and polynucleotides encoding the same
06/27/2002CA2423331A1 Shark meat extract
06/27/2002CA2397990A1 Propofol formulation with enhanced microbial inhibition
06/26/2002EP1217002A1 2-(4-pyridinyl)-benzofurans as metalloprotease inhibitors
06/26/2002EP1217001A1 Quinuclidine compounds and drugs containing the same as the active ingredient
06/26/2002EP1217000A1 Inhibitors of factor Xa and factor VIIa
06/26/2002EP1216996A2 Method to synthesise biphenylyl derivatives
06/26/2002EP1216713A1 Compositions of estrogen-cyclodextrin complexes
06/26/2002EP1216712A1 Cyclodextrin-drospirenone inclusion complexes
06/26/2002EP1216705A2 The use of growth factor modulation compounds substituted with three vicinal phosphorus containing radical in the manufacture of a medicament for tissue repair
06/26/2002EP1216704A1 Controlled release valproate composition
06/26/2002EP1216703A2 Thiocarbamate sulfoxide composition for deterring ethanol ingestion
06/26/2002EP1216702A2 Aminotetralin derivative for the therapy of cardiovascular diseases
06/26/2002EP1216701A1 Process to increase the concentration of meiosis-activating sterols (MAS) in the cholesterol synthesis and the use of potent inhibitors in the process
06/26/2002EP1216700A1 Transdermal systems comprising (R)-(-)-methylphenyloxazolidinone derivatives, inhibitors of type IV phosphodiesterase
06/26/2002EP1216699A1 Transdermal system comprising a highly potent progestin
06/26/2002EP1216696A2 Method for reducing the appearance of dark circles under the eyes
06/26/2002EP1216694A1 Combinations of surface-active citric acid esters and alpha lipoic acid , as well as cosmetic and dermatological preparations with a content of said mixtures
06/26/2002EP1216692A2 Use of chroman derivatives in cosmetic and dermatological preparations
06/26/2002EP1216685A2 Personal care compositions
06/26/2002EP1216625A1 The use of a non-absorbable, non-digestible lipid for the treatment of hyperbilirubinemia
06/26/2002EP1216309A2 Methods for targeting rna molecules
06/26/2002EP1216257A1 Compounds for the treatment of ischemia
06/26/2002EP1216250A1 Thienoisoxazolyl and thienylpyrrazolyl phenoxy substituted propyl derivatives useful as d4 antagonists
06/26/2002EP1216249A2 Thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives useful as d4 antagonists
06/26/2002EP1216248A2 Triazolopyrimidine derivatives
06/26/2002EP1216247A1 Imidazoimidazoles and triazoles as anti-inflammatory agents
06/26/2002EP1216246A1 N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
06/26/2002EP1216245A1 Pharmaceutically active sulfonyl hydrazide derivatives
06/26/2002EP1216244A1 Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as d 4? antagonists
06/26/2002EP1216241A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
06/26/2002EP1216240A1 Amide compounds
06/26/2002EP1216239A1 Piperazine derivatives as 5-ht1b antagonists
06/26/2002EP1216238A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
06/26/2002EP1216236A1 Tryptase inhibitors
06/26/2002EP1216234A2 Mediators of hedgehog signaling pathways, compositions and uses related thereto
06/26/2002EP1216232A1 Heterocyclic compounds and methods for modulating cxcr3 function
06/26/2002EP1216231A2 INHIBITORS OF FACTOR Xa
06/26/2002EP1216230A2 Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists
06/26/2002EP1216228A2 BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
06/26/2002EP1216225A2 Novel derivatives of dicarboxylic acid having pharmaceutical properties
06/26/2002EP1216223A1 Novel dicarboxylic acid derivatives with pharmaceutical properties